| Sign In to gain access to subscriptions and/or personal tools. |
DOI: 10.1191/0961203304lu1089oa European register of babies born to mothers with antiphospholipid syndromeDepartment of Internal Medicine, Hôpital de la Pitié, Paris, France, marie-claire.boffa{at}psl.ap-hop-paris.fr
Department of Hematology, Hôpital Jean Verdier, Bondy, France
Department of Pediatrics, Hôpital Jean Verdier, Bondy, France
Department of Obstetrics and Gynecology, Hôpital Jean Verdier, Bondy, France
Department of Internal Medicine, Hôpital Jean Verdier, Bondy, France
Department of Epidemiology, Biobigny, UPRES EA 3409, France
Department of Obstetrics and Gynecology, Hôpital Jean Verdier, Bondy, France
Department of Internal Medicine, Hôpital de la Pitié, Paris, France
CHU Hôtel-Dieu, Nantes, France
CHU La Milétrie, Poitiers, France
University Childrens Hospital Ljubljana, Slovenia
Spedali Civili di Brescia, Brescia, Italy
Spedali Civili di Brescia, Brescia, Italy
Spedali Civili di Brescia, Brescia, Italy This prospective multicentric register was initiated by the European Forum of Antiphospholipid Antibodies (APL) in 2003 after approval by local ethic committees. This register allows the investigation of infants after written informed parental consent. It collects mothers clinical pattern of antiphospholipid syndrome (APS), course and outcome of pregnancy, treatment and immunological status. For the babies, clinical and immunological examinations are performed at birth; neuro-developmental conditions followed up to five years. A re-evaluation of lupus anticoagulant (LA), anticardiolipin (ACL) or other antibodies will be done if they are positive at birth to follow their kinetics. A descriptive and a case control study of babies with versus without APL at birth will be possible after the inclusion of 300 cases.
Key Words: anticardiolipin antibodies antiphospholipid antibodies babies development of babies infants lupus anticoagulant neonates obstetrical complications prematurity
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

